Advances in systemic therapy for non-small cell lung cancer

ABSTRACTLung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgic...

Full description

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2021-11, Vol.375, p.n2363-n2363
Main Authors: Miller, Meagan, Hanna, Nasser
Format: Article
Language:English
Subjects:
20th century
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical medicine
Clinical Review
Clinical trials
Cytotoxicity
Immunotherapy
Lung cancer
Metastasis
Mutation
Non-small cell lung carcinoma
Patients
Radiation therapy
Small cell lung carcinoma
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTLung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
ISSN:1756-1833
1756-1833
DOI:10.1136/bmj.n2363